Keymed Biosciences Inc. (2162.HK)
- Previous Close
45.000 - Open
46.000 - Bid 42.300 x --
- Ask 42.400 x --
- Day's Range
42.100 - 46.300 - 52 Week Range
27.050 - 49.600 - Volume
2,512,999 - Avg. Volume
2,190,315 - Market Cap (intraday)
11.72B - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
-- - EPS (TTM)
-2.090 - Earnings Date Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
59.27
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing CM338, an antagonist antibody against mannose-binding lectin associated serine protease-2. Additionally, it is developing CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
www.keymedbio.comRecent News: 2162.HK
View More
Performance Overview: 2162.HK
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2162.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2162.HK
View MoreValuation Measures
Market Cap
12.48B
Enterprise Value
10.99B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.95
Price/Book (mrq)
4.75
Enterprise Value/Revenue
24.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-120.35%
Return on Assets (ttm)
-10.23%
Return on Equity (ttm)
-18.85%
Revenue (ttm)
428.12M
Net Income Avi to Common (ttm)
-515.24M
Diluted EPS (ttm)
-2.090
Balance Sheet and Cash Flow
Total Cash (mrq)
2.16B
Total Debt/Equity (mrq)
30.43%
Levered Free Cash Flow (ttm)
--